Most Recent
Honda has admitted to the Australian Competition and Consumer Commission's claims that it mislead the customers of two former authorised dealerships, but is seeking to avoid pecuniary penalties for the “accidental” misconduct.
A government-approved plan to build a waste facility in western Tasmania has been parked, after environmental campaigners won a judgment declaring the federal government’s approval of the proposed tailings storage facility was invalid.
The Australian Taxation Office has finalised its protocol for dealing with claims of legal professional privilege, developed in response to large companies asserting "reckless" privilege claims which the ATO says obstruct its investigations.
The Full Federal Court has rejected an Australian inventor’s appeal of a ruling that found three manufacturers of essential oil products did not infringe his patent because the oil was a “staple commercial product”.
The Australian Labor Party has won an emergency court order for the removal of allegedly misleading how-to-vote signs at polling stations in the closely watched race in the Melbourne electorate of Higgins.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim's appeal of ruling that shot down its opposition to Merck Sharp & Dohme's patent application for an injectable anti-parasite drug for livestock.
A judge has slapped Trivago with $44.7 million in penalties for a "startlingly misleading" rankings system used on its travel comparison website from which it reaped $53 million.
Telecommunications giant SingTel is challenging a ruling in favour of the Australian Taxation Office's decision to reject over $894,000 in tax deductions related to its $14.2 billion acquisition of Optus.
The Full Court has overturned a landmark judgment which found artificial intelligence can be named as an inventor on patent applications, in a decision which brings Australia in line with findings from courts in the UK, US and EU.
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.